These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 930746)

  • 1. CNS compensation to dopamine neuron loss in Parkinson's disease.
    Lloyd KG
    Adv Exp Med Biol; 1977; 90():255-66. PubMed ID: 930746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 3. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.
    Piggott MA; Perry EK; Marshall EF; McKeith IG; Johnson M; Melrose HL; Court JA; Lloyd S; Fairbairn A; Brown A; Thompson P; Perry RH
    Biol Psychiatry; 1998 Oct; 44(8):765-74. PubMed ID: 9798081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vitamin B-6 nutrition on the levels of dopamine, dopamine metabolites, dopa decarboxylase activity, tyrosine, and GABA in the developing rat corpus striatum.
    Guilarte TR
    Neurochem Res; 1989 Jun; 14(6):571-8. PubMed ID: 2761676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurochemical aspects of parkinsonism. Review of the literature].
    De Mattos JP; Cechela C; Adams JG; De Lima JM
    Arq Neuropsiquiatr; 1982 Sep; 40(3):289-95. PubMed ID: 6130754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems.
    Zhou FM; Wilson C; Dani JA
    Neuroscientist; 2003 Feb; 9(1):23-36. PubMed ID: 12580337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism.
    Zeevalk GD; Manzino L; Hoppe J; Sonsalla P
    Eur J Pharmacol; 1997 Feb; 320(2-3):111-9. PubMed ID: 9059843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
    Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
    Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat.
    González-Hernández T; Barroso-Chinea P; Rodríguez M
    Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling.
    Lemos JC; Friend DM; Kaplan AR; Shin JH; Rubinstein M; Kravitz AV; Alvarez VA
    Neuron; 2016 May; 90(4):824-38. PubMed ID: 27196975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes.
    Bak IJ; Hassler R; Kim JS; Kataoka K
    J Neural Transm; 1972; 33(1):45-61. PubMed ID: 4674484
    [No Abstract]   [Full Text] [Related]  

  • 18. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
    Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
    Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
    Anglade P; Tsuji S; Javoy-Agid F; Agid Y; Hirsch EC
    Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.